Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neumora Therapeutics, Inc. (NMRA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Neumora uses current reports on Form 8-K and other filings to communicate material information about its financial condition, capital structure and key pipeline events.
In recent 8-K filings, Neumora has reported quarterly financial results, including details on research and development and general and administrative expenses, net loss and cash, cash equivalents and marketable securities. These filings also reference the company’s expectation that its available capital will fund its operating plan into 2027, based on the specific reporting dates. Other 8-Ks describe business updates such as the initiation of a Phase 1 SAD/MAD study of NMRA-898, a positive preclinical data announcement for NMRA-215, and the associated press releases furnished or filed as exhibits.
Neumora has also filed an 8-K describing a conversion under its Loan and Security Agreement with K2 HealthVentures LLC, in which a portion of the outstanding term loan principal was converted into shares of common stock. This filing outlines the conversion terms, the number of shares issued and the reliance on a registration exemption under the Securities Act of 1933.
On Stock Titan, Neumora’s SEC filings are updated as they appear on EDGAR, and AI-powered summaries help explain the key points in plain language. Users can review current reports on Form 8-K for material events, track changes related to financing arrangements, and connect these disclosures with the company’s broader clinical and business narrative. This page is a resource for understanding how Neumora reports its financial results, capital transactions and significant pipeline milestones to regulators and investors.
Neumora Therapeutics, Inc. reported that its lender K2 HealthVentures exercised a conversion right under an existing Loan and Security Agreement. K2 HealthVentures converted $2.5 million of term loan principal into common stock at a price of $0.8774 per share, as allowed under the agreement that permits conversion of up to $12.5 million of principal. On November 20, 2025, Neumora issued 2,849,327 shares of common stock to K2 HealthVentures Equity Trust LLC in connection with this conversion. The shares were issued as a private offering relying on the registration exemption in Section 4(a)(2) of the Securities Act of 1933.
Neumora Therapeutics (NMRA) officer Daljit Singh Aurora reported an open-market sale of 114,703 shares of common stock on 11/11/2025 at a weighted average price of $2.6767. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024, and the sold shares were held by the Aurora Family Trust. Following the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.
Neumora Therapeutics reported a Q3 2025 net loss of $56.8 million, with nine‑month net loss at $177.5 million. Operating expenses fell year over year as research and development declined to $40.5 million from $60.6 million, and general and administrative to $12.2 million from $16.0 million. The company recorded $5.0 million of acquired in‑process R&D tied to its Vanderbilt M4 program.
Cash, cash equivalents and marketable securities totaled $171.5 million as of September 30, 2025. Neumora believes this will fund operations for at least the next 12 months. In May, it drew $20.0 million from a term loan facility with K2 HealthVentures (up to $125.0 million across tranches) at a minimum rate of 10.45%, and subsequently borrowed an additional $40.0 million after quarter‑end.
The pipeline includes a Phase 3 program for navacaprant in major depressive disorder and a Phase 1b study for NMRA‑511 in agitation due to Alzheimer’s disease, with early‑stage M4 PAM candidates advancing. Shares outstanding were 167,089,114 as of November 1, 2025.
Neumora Therapeutics, Inc. furnished an 8-K stating it announced financial results for the second quarter ended September 30, 2025. The full details are provided in a press release attached as Exhibit 99.1.
The company notes that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. The report was signed by Chief Financial Officer Michael Milligan on November 6, 2025.
Neumora Therapeutics (NMRA) insider filing: Director and 10% owner Kristina Burow reported a purchase of 1,915,700 shares of common stock at $2.61 on 10/27/2025, recorded as an indirect transaction by ARCH Venture Fund XII, L.P.
Following the transaction, reported beneficial holdings include: 6,046,907 shares indirectly via ARCH Venture Fund XII, L.P.; 1,387,228 via ARCH Venture Fund VII, L.P.; 2,321,566 via ARCH Venture Fund VIII Overage, L.P.; 12,205,379 via ARCH Venture Fund X, L.P.; 11,886,758 via ARCH Venture Fund X Overage, L.P.; and 47,717 shares held directly.
Neumora Therapeutics (NMRA) insider filing reports an open-market purchase by affiliated ARCH Venture funds. On 10/27/2025, the reporting persons acquired 1,915,700 shares of common stock at $2.61 per share, reported as indirectly owned.
Following the transaction, indirect beneficial holdings were listed as: 6,046,907 shares by ARCH Venture Fund XII, L.P.; 1,387,228 by ARCH Venture Fund VII, L.P.; 2,321,566 by ARCH Venture Fund VIII Overage, L.P.; 12,205,379 by ARCH Venture Fund X, L.P.; and 11,886,758 by ARCH Venture Fund X Overage, L.P. The filing is a joint submission, and a director relationship is indicated.
Neumora Therapeutics (NMRA): ARCH-affiliated reporting persons disclosed an insider purchase. On 10/27/2025, ARCH Venture Fund XII, L.P. bought 1,915,700 shares of common stock at $2.61 per share (Transaction Code P), reported as indirect ownership.
After the transaction, beneficial holdings reported include: 6,046,907 (ARCH XII); 12,205,379 (ARCH Venture Fund X, L.P.); 11,886,758 (ARCH Venture Fund X Overage, L.P.); 2,321,566 (ARCH Venture Fund VIII Overage, L.P.); and 1,387,228 (ARCH Venture Fund VII, L.P.). The filing was made jointly by multiple ARCH entities and certain individuals, with the relationship indicated as Director.
Neumora Therapeutics (NMRA) reported an operational update under Item 8.01. On October 27, 2025, the company announced the initiation of a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-898. The related press release was furnished as Exhibit 99.1.
This is an early clinical development milestone disclosed via an 8-K and does not include financial results or guidance.
Neumora Therapeutics (NMRA) filed an 8‑K announcing positive preclinical data for NMRA‑215. The company reported class‑leading weight loss in diet‑induced obesity mouse studies: up to 19% as a monotherapy with semaglutide‑like induction, and 26% when combined with high doses of semaglutide. The announcement was made on October 27, 2025.
A press release with additional details was furnished as Exhibit 99.1 and incorporated by reference.
Neumora Therapeutics disclosed that K2 HealthVentures Equity Trust LLC and two managing members, Parag Shah and Anup Arora, report beneficial ownership tied to convertible debt that can be converted into Common Stock. Under a loan and security agreement, K2HV Equity has the right to convert up to $10,000,000 of principal into Conversion Shares at the lesser of $0.8774 per share or the lowest effective price in the Issuer's next equity financing; the filers assumed the $0.8774 conversion price.
As a result, the Reporting Persons disclose beneficial ownership of 11,397,310 shares, representing approximately 6.6% of Common Stock on a converted basis. The Schedule shows shared voting and dispositive power over those shares (no sole voting or dispositive power). The reporting address for the filers is provided as 855 Boylston Street, Boston, MA.